Annovis Hits Key Milestones in Alzheimer’s and Parkinson’s Trials
Event summary
- Annovis’ Phase 3 Alzheimer’s trial is 85% enrolled, with full enrollment expected by summer 2026.
- Parkinson’s open-label extension study is 40% enrolled, targeting completion by Q4 2026.
- NDA submission for buntanetap as a symptomatic Alzheimer’s treatment is planned for early 2027.
- Company raised $10 million in April 2026, ending Q1 with $14.2 million in cash.
- Q1 2026 R&D expenses surged to $16.7 million, up from $5.0 million in Q1 2025.
The big picture
Annovis is advancing its lead candidate, buntanetap, through critical late-stage trials for Alzheimer’s and Parkinson’s diseases. The company’s progress reflects the growing focus on multi-protein targeting in neurodegeneration, though its path to commercialization hinges on successful regulatory interactions and sustained investor support. With $14.2 million in cash as of Q1 2026, Annovis must balance aggressive clinical development with financial prudence.
What we're watching
- Regulatory Pathway
- Whether Annovis can secure FDA approval for buntanetap as both a symptomatic and disease-modifying treatment by 2028.
- Execution Risk
- The pace at which Annovis completes enrollment and generates pivotal data for both Alzheimer’s and Parkinson’s trials.
- Financial Sustainability
- How long Annovis’ current cash position will last amid rising R&D expenses and potential future funding needs.
Related topics